Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 56Breast Neoplasms 49Ovarian Neoplasms 31Triple Negative Breast Neoplasms 27Endometrial Neoplasms 25Lung Neoplasms 24Fallopian Tube Neoplasms 22Neoplasm Metastasis 21Squamous Cell Carcinoma of Head and Neck 19Parkinson Disease 4, Autosomal Dominant Lewy Body 18Neoplasms 14Esophageal Squamous Cell Carcinoma 12Esophageal Neoplasms 12Carcinoma, Ovarian Epithelial 9Stomach Neoplasms 8Head and Neck Neoplasms 8Colorectal Neoplasms 8Carcinoma 7Adenocarcinoma Of Esophagus 7Peritoneal Neoplasms 6Adenocarcinoma 6Uterine Cervical Neoplasms 5Melanoma 5Oropharyngeal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Recurrence 3Pancreatic Neoplasms 3

Interventions

cemiplimab 1Pemetrexed 1Paclitaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Non-small Cell Lung Cancer × Paclitaxel × 90 days × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡